Nuwellis (NUWE) AI Stock Analysis

• Market Cap: $2.83M
• Dividend Yield: N/A
• Average Volume (3M): 289.18K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.11
• Revenue Growth: -7.72%
• EPS Growth: 99.54%
• Country: US
• Employees: 38
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -60.99
• Shares Outstanding: 902,665
• 10 Day Avg. Volume: 82,161
• 30 Day Avg. Volume: 289,177
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: -0.74
• Enterprise Value/Revenue: -0.25
• Enterprise Value/Gross Profit: -0.42
• Enterprise Value/Ebitda: 0.53
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 43 Neutral
• Price Target: $3.00 ▼(-0.99% Downside)

Nuwellis's overall stock score is primarily impacted by its financial performance, which is marked by ongoing losses and negative cash flows. Technical analysis further reflects bearish sentiment, while valuation metrics indicate potential overvaluation. The earnings call provides some optimism with strategic initiatives, but immediate financial challenges remain significant.

Positive Factors

Pediatric Revenue Growth

Strong growth in pediatric revenues indicates increasing demand and successful market penetration in a specialized segment, supporting long-term revenue stability.

New Patent Issuance

The new patent strengthens Nuwellis' IP portfolio, enhancing competitive advantage and supporting future product innovation, particularly in pediatric care.

NIH Grant for Pediatric Device

The NIH grant supports critical development of pediatric devices, potentially expanding market reach and reinforcing Nuwellis' position in pediatric healthcare solutions.

Negative Factors

Overall Revenue Decline

A significant revenue decline poses challenges for financial stability and growth, necessitating strategic adjustments to reverse the trend and sustain operations.

Gross Margin Decrease

Reduced gross margins due to lower production volumes impact profitability, highlighting the need for cost management and operational efficiency improvements.

Increased Operating Loss

Rising operating losses indicate ongoing financial strain, underscoring the necessity for strategic cost reductions and revenue enhancement to achieve profitability.

Nuwellis Business Overview & Revenue Model

Company Description

Nuwellis, Inc., a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics. Its Aquadex FlexFlow system includes a console, disposable blood set, and catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors primarily in Austria, Brazil, Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.

How the Company Makes Money

Nuwellis generates revenue through the sale of its medical devices and related products, which are sold to hospitals, healthcare providers, and clinics. The company's revenue model is primarily based on direct sales of its proprietary fluid management devices, as well as recurring revenue from consumables and accessories that accompany these devices. Key revenue streams include product sales, service contracts, and potential licensing agreements. Additionally, Nuwellis may benefit from partnerships with healthcare institutions and collaborations with other medical technology companies, which can enhance market reach and provide access to new customer segments.

Nuwellis Financial Statement Overview

Summary

Nuwellis faces significant financial challenges marked by consistent losses and negative cash flows, despite stable revenue and a strong equity position. The company needs to focus on improving operational efficiency and profitability to ensure long-term sustainability.

Income Statement

Nuwellis demonstrates modest revenue growth with a 2.8% increase from 2022 to 2023 and a slight decline of 1.4% in 2024. However, the company is grappling with negative profitability as evidenced by significant negative EBIT and net income margins. Despite a decent gross profit margin of approximately 64.9% for 2024, ongoing losses due to high operational costs are concerning.

Balance Sheet

The company's balance sheet shows a healthy equity position with an equity ratio of 66.2% in 2024, indicating a strong buffer against liabilities. However, the debt-to-equity ratio stands at 0.08, showcasing manageable leverage but returns on equity remain negative due to sustained net losses. The stability is commendable, yet profitability remains a critical issue.

Cash Flow

Cash flow analysis reflects a challenging situation with negative free cash flow, although there is a marked improvement in operating cash flow from 2023 to 2024. The company's reliance on financing activities for liquidity is evident. Free cash flow growth remains negative, indicating ongoing cash burn issues which could impact future operations if not addressed.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	8.32M	8.74M	8.86M	8.54M	7.92M	7.44M
Gross Profit	5.04M	5.68M	4.98M	4.75M	4.49M	4.06M
EBITDA	-3.96M	-5.24M	-16.36M	-4.90M	-19.06M	-16.65M
Net Income	-14.68M	-10.62M	-20.21M	-14.53M	-19.58M	-15.84M
Balance Sheet
Total Assets	9.20M	9.86M	9.77M	24.67M	30.42M	20.01M
Cash, Cash Equivalents and Short-Term Investments	4.45M	5.09M	3.80M	18.31M	24.20M	14.44M
Total Debt	438.00K	545.00K	760.00K	984.00K	1.18M	339.00K
Total Liabilities	18.16M	3.33M	6.56M	12.32M	4.47M	3.69M
Stockholders Equity	-8.96M	6.53M	3.21M	12.36M	25.95M	16.32M
Cash Flow
Free Cash Flow	-8.62M	-9.65M	-18.18M	-15.27M	-18.06M	-16.87M
Operating Cash Flow	-8.61M	-9.59M	-17.94M	-15.15M	-17.84M	-16.57M
Investing Cash Flow	-11.00K	-60.00K	330.00K	14.73M	-15.72M	-267.00K
Financing Cash Flow	12.06M	10.96M	3.68M	9.42M	27.87M	30.02M

Nuwellis Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.03
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NUWE, the sentiment is Negative. The current price of 3.03 is below the 20-day moving average (MA) of 3.44, below the 50-day MA of 4.20, and below the 200-day MA of 26.53, indicating a bearish trend. The MACD of -0.33 indicates Negative momentum. The RSI at 30.33 is Neutral, neither overbought nor oversold. The STOCH value of 7.28 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NUWE.

Nuwellis Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
VERO	45 Neutral	$4.11M	-0.04	-1371.21%	―	-13.90%	44.89%
NUWE	43 Neutral	$2.83M	-0.09	―	―	-7.72%	99.54%
SINT	42 Neutral	$11.65M	-0.33	-195.48%	―	-40.47%	96.14%
VTAK	41 Neutral	$3.79M	-0.03	-179.11%	―	37.61%	68.37%
AMIX	40 Underperform	$7.00M	―	-195.55%	―	―	65.72%
HIND	37 Underperform	$29.94M	-0.01	-101.49%	―	-19.81%	93.32%

Nuwellis Corporate Events

Nuwellis Appoints John L. Erb as Interim CFO

On October 7, 2025, Robert B. Scott announced his resignation as Chief Financial Officer of Nuwellis, Inc., effective around October 24, 2025. His departure is not due to any disagreements with the company. The company plans to initiate a search for a new CFO. On October 8, 2025, the Board appointed John L. Erb, the current President and CEO, as interim CFO starting on the separation date. Mr. Erb has extensive experience in the medical device industry and has held various leadership roles within Nuwellis and other companies. His appointment as interim CFO is not accompanied by any additional compensation or changes to his current plans.

The most recent analyst rating on (NUWE) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on Nuwellis stock, see the NUWE Stock Forecast page.

Nuwellis Announces ULTRA-Peds Registry Findings

On September 30, 2025, Nuwellis, Inc. announced findings from the ULTRA-Peds registry, a multi-center observational study examining the real-world use of the Aquadex System in children with acute kidney injury (AKI), fluid overload, or congenital kidney failure.

The most recent analyst rating on (NUWE) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on Nuwellis stock, see the NUWE Stock Forecast page.

Nuwellis Secures New Patent for Hemolysis Sensors

On September 18, 2025, Nuwellis, Inc. announced the issuance of a new U.S. patent related to hemolysis sensors in blood filtration systems, which supports their pediatric device, Vivian, and future innovations. This patent issuance strengthens Nuwellis’ intellectual property portfolio, potentially enhancing their market position and innovation capabilities in the medical device sector.

The most recent analyst rating on (NUWE) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on Nuwellis stock, see the NUWE Stock Forecast page.

Nuwellis Secures NIH Grant for Pediatric Device Development

On September 9, 2025, Nuwellis, Inc. announced that the National Institutes of Health (NIH) awarded a multi-year grant of approximately $3 million to its partner, Koronis Biomedical Technologies Corporation. This grant will expedite the development of Vivian™, a pediatric continuous renal replacement therapy device, and enhance the company’s software and firmware, potentially strengthening its market position.

The most recent analyst rating on (NUWE) stock is a Hold with a $5.50 price target. To see the full list of analyst forecasts on Nuwellis stock, see the NUWE Stock Forecast page.

Nuwellis Announces At The Market Offering Agreement

On September 3, 2025, Nuwellis entered into an At The Market Offering Agreement with Ladenburg Thalmann & Co. Inc. to sell shares of its common stock, with an initial aggregate offering price of up to $4,650,000. The company is not obligated to sell any shares and will pay Ladenburg a commission of up to 3% of the gross proceeds from any sales made. This agreement allows Nuwellis flexibility in raising capital while providing Ladenburg with indemnification rights and expense reimbursements.

The most recent analyst rating on (NUWE) stock is a Hold with a $5.50 price target. To see the full list of analyst forecasts on Nuwellis stock, see the NUWE Stock Forecast page.

Nuwellis, Inc. Earnings Call: Challenges and Strategic Initiatives

Nuwellis, Inc. recently held its earnings call, revealing a mixed sentiment regarding its financial performance and strategic initiatives. While the company is making strides in areas such as pediatric revenue growth and operational transitions, it faces immediate challenges with declining revenues and increased losses. The call highlighted both the potential for future growth and the current financial hurdles that need to be addressed.

Nuwellis Gains FDA Clearance for New Catheter

On August 21, 2025, Nuwellis, Inc. announced that it has received FDA 510(k) clearance for a new size of its Dual Lumen Extended Length Catheter (dELC). This clearance may enhance the company’s product offerings and potentially improve its market position in the medical device industry.

The most recent analyst rating on (NUWE) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on Nuwellis stock, see the NUWE Stock Forecast page.

Nuwellis Announces Acquisition of Rendiatech, Ltd.

On August 19, 2025, Nuwellis, Inc. announced its intention to acquire Rendiatech, Ltd., an Israeli company specializing in urine flow and kidney monitoring technologies. This acquisition aims to enhance Nuwellis’ technology platform by incorporating continuous renal health monitoring, potentially offering clinicians better insights into fluid status and kidney function. The deal is expected to close in the fourth quarter of 2025, subject to due diligence, board approval, and closing conditions.

The most recent analyst rating on (NUWE) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on Nuwellis stock, see the NUWE Stock Forecast page.

Nuwellis, Inc. Reports Q2 2025 Financial Results

Nuwellis, Inc. is a commercial-stage medical technology company focused on providing innovative solutions for fluid overload patients, primarily through its Aquadex SmartFlow system. The company operates in the medical device sector and is headquartered in Minneapolis, Minnesota.

Nuwellis Approves Stock Proposals at Special Meeting

On August 4, 2025, Nuwellis, Inc. held a virtual special meeting of stockholders to discuss several key proposals. The meeting sought approval for the issuance of common stock shares, an increase in authorized shares from 100 million to 200 million, and a reverse stock split to comply with Nasdaq listing requirements. The proposals were approved by a majority vote, with the reverse split aimed at maintaining the company’s Nasdaq listing status.

The most recent analyst rating on (NUWE) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on Nuwellis stock, see the NUWE Stock Forecast page.

Nuwellis Regains Nasdaq Compliance After Delisting Risk

Nuwellis, Inc. received a notice from Nasdaq on June 18, 2025, indicating that its stock price had fallen below $1.00 per share for 30 consecutive trading days, putting it at risk of delisting. However, by July 22, 2025, the company had resolved the issue, and Nasdaq confirmed that Nuwellis was back in compliance with listing standards, allowing its stock to continue trading on the Nasdaq Capital Market.

The most recent analyst rating on (NUWE) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on Nuwellis stock, see the NUWE Stock Forecast page.